Regenerex Pharma, Inc. Files 10-Q for Period Ended December 31, 2023

TL;DR

<b>Regenerex Pharma, Inc. filed its quarterly report (10-Q) for the period ending December 31, 2023.</b>

AI Summary

REGENEREX PHARMA, INC. (RGPX) filed a Quarterly Report (10-Q) with the SEC on February 5, 2024. Regenerex Pharma, Inc. filed a 10-Q report for the period ending December 31, 2023. The company's fiscal year ends on March 31. The filing covers the third quarter of 2023. The company was formerly known as PEPTIDE TECHNOLOGIES, INC. and Eternelle Skincare Products Inc. The business and mailing address is 5348 Vegas Drive, Suite 177, Las Vegas, NV 89108.

Why It Matters

For investors and stakeholders tracking REGENEREX PHARMA, INC., this filing contains several important signals. This filing provides an update on the company's financial performance and operational status for the specified quarter. Understanding the details within this 10-Q is crucial for investors and stakeholders to assess the company's current financial health and future prospects.

Risk Assessment

Risk Level: low — REGENEREX PHARMA, INC. shows low risk based on this filing. The filing is a standard 10-Q, providing routine financial updates without immediate indicators of significant risk or opportunity.

Analyst Insight

Monitor future filings for revenue growth, net income, and any significant changes in debt or cash positions.

Key Numbers

• 2023-12-31 — Period of Report (Quarterly report end date)
• 2024-02-05 — Filing Date (Date the report was filed)
• 0331 — Fiscal Year End (Company's fiscal year end month and day)
• 2023-10-01 — Quarter Start Date (Start date for the reported quarter)
• 2023-12-31 — Quarter End Date (End date for the reported quarter)

Key Players & Entities

• REGENEREX PHARMA, INC. (company) — Filer name
• RGPX (company) — Ticker symbol
• PEPTIDE TECHNOLOGIES, INC. (company) — Former company name
• Eternelle Skincare Products Inc. (company) — Former company name
• 2023-12-31 (date) — Period of report
• 2024-02-05 (date) — Filing date
• 5348 VEGAS DRIVE, SUITE 177 (address) — Business address
• LAS VEGAS, NV (location) — Business address city and state

FAQ

Industry Context

Regenerex Pharma, Inc. operates within the Pharmaceutical Preparations industry (SIC code 2834).

Regulatory Implications

The filing is a 10-Q, a quarterly report required by the Securities Exchange Act of 1934 for publicly traded companies.

What Investors Should Do

1. Review the full 10-Q document for detailed financial statements and management discussion.
2. Analyze revenue, net income, and cash flow trends in subsequent filings.
3. Research any specific disclosures regarding product development or regulatory matters mentioned in the report.

Key Dates

• 2023-12-31: Period End Date — End date of the reporting quarter for the 10-Q filing.
• 2024-02-05: Filing Date — Date the 10-Q report was officially filed with the SEC.

Year-Over-Year Comparison

This is the initial analysis of the 10-Q filing for the period ending December 31, 2023. No prior filing data is available for direct comparison within this extract.

Key Financial Figures

• $0.001 — ding at February 5, 2024 Common stock, $0.001 par value 277,995,910 "Explanatory N
• $500 — s are capitalized while purchases under $500 are expensed as incurred. 6 Right of
• $200,500 — ounts totaling approximately $ 154,000 ($200,500 Canadian dollars) that came due during
• $240,600 — ipal amount of approximately $ 185,000 ($240,600 Canadian dollars) which included the pr
• $40,100 — ued interest of approximately $ 31,000 ($40,100 Canadian dollars). During the nine mon
• $3,844 — ry note totaling approximately $ 2,800 ($3,844 Canadian dollars). This note is unsecur
• $10,000,000 — f the Company's common stock and up to $10,000,000 in contingent consideration to be paid
• $2,400,000 — million four hundred thousand dollars ($2,400,000) note payable. The intellectual propert

Filing Documents

• ixform10q.htm (10-Q) — 419KB
• exhibit31-1.htm (EX-31.1) — 11KB
• exhibit31-2.htm (EX-31.2) — 12KB
• exhibit32-1.htm (EX-32.1) — 4KB
• exhibit32-2.htm (EX-32.2) — 4KB
• regenerexlogo.gif (GRAPHIC) — 6KB
• 0001472375-24-000005.txt (&nbsp;) — 2312KB
• rgpx-20231231.xsd (EX-101.SCH) — 20KB
• rgpx-20231231_cal.xml (EX-101.CAL) — 31KB
• rgpx-20231231_def.xml (EX-101.DEF) — 93KB
• rgpx-20231231_lab.xml (EX-101.LAB) — 168KB
• rgpx-20231231_pre.xml (EX-101.PRE) — 145KB
• ixform10q_htm.xml (XML) — 169KB

forward-looking statements. Actual results or events could differ materially from

forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding: our ability to add new customers; the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position and cash flows; the potential benefits of and our ability to maintain our relationships, and establish or maintain future collaborations or strategic relationships or obtain additional funding; our marketing capabilities and strategy; our ability to maintain a cost-effective program; our ability to retain the continued service of our key professionals and to identify, hire and retain additional qualified professionals; our competitive position, and developments and projections relating to our competitors and our industry; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and the impact of laws and regulations. All of our

forward-looking statements are as of the date of this Quarterly Report on Form

forward-looking statements are as of the date of this Quarterly Report on Form 10-Q only. In each case, actual results may differ materially from such forward-looking information. We can give no assurance that such expectations or

forward-looking statements will prove to be correct. An occurrence of, or any

forward-looking statements will prove to be correct. An occurrence of, or any material adverse change in, one or more of the risk factors or risks and uncertainties referred to in this Quarterly Report on Form 10-Q or included in our other public disclosures or our other periodic reports or other documents or filings filed with or furnished to the U.S. Securities and Exchange Commission (the "SEC") could materially and adversely affect our business, prospects, financial condition and results of operations. Except as required by law, we do not undertake or plan to update or revise any such forward-looking statements to reflect actual results, changes in plans, assumptions, estimates or projections or other circumstances affecting such forward-looking statements occurring after the date of this Quarterly Report on Form 10-Q, even if such results, changes or circumstances make it clear that any forward-looking information will not be realized. Any public statements or disclosures by us following this Quarterly Report on Form 10-Q that modify or impact any of the

forward-looking statements contained in this Quarterly Report on Form 10-Q will

forward-looking statements contained in this Quarterly Report on Form 10-Q will be deemed to modify or supersede such statements in this Quarterly Report on Form 10-Q. REGENEREX PHARMA, INC. I NDEX TO FORM 10-Q FILING FOR THE NINE MONTHS ENDED DECEMBER 31, 2023 AND 2022 TABLE OF CONTENTS PAGE

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION Item 1.

Financial Statements (Unaudited)

Financial Statements (Unaudited) 1 Balance Sheets 1 2 3 4

Notes to Financial Statements

Notes to Financial Statements 5 Item 2. Management Discussion & Analysis of Financial Condition and Results of Operations 12 Item 3

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 17 Item 4.

Controls and Procedures

Controls and Procedures 17

- OTHER INFORMATION

PART II - OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 19 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 19 Item 3. Defaults Upon Senior Securities 19 Item 4. Mining Safety Disclosures 19 Item 5 Other Information 19 Item 6. Exhibits 19 CERTIFICATIONS 31.1 Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 31.2 Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act 32.1 Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act 32.2 Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act PART I FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS REGENEREX PHARMA, INC. BALANCE SHEETS (UNAUDITED) December 31, 2023 March 31, 2023 ASSETS Current Assets Cash and equivalents $ 7,856 $ 1,135 Prepaid expenses 1,423 — Total Current Assets 9,279 1,135 Website, net of accumulated amortization of $ 28,557 and $ 26,397 , respectively 2,043 4,203 Furniture and computer equipment, net of accumulated amortization of $ 1,170 and $ 197 , respectively 6,527 1,201 Right of use asset 834,293 — Total Assets $ 852,142 $ 6,539 LIABILITIES AND STOCKHOLDERS' DEFICIT Current Liabilities Accounts payable $ 78,950 $ 75,145 Related party advances 4,757 131,887 Accrued compensation 414,962 221,192 Other accrued liabilities 83,227 125,787 Current portion of notes payable to shareholder 322,246 222,771 Current portion of notes payable to related parties 103,500 — Current portion of notes payable 2,400,000 — Current portion of lease liabilities 152,046 — Total Current Liabilities 3,559,688 776,782 Notes payable to shareholder, net of current portion 260,788 314,704 Notes payable to related parties, net of current portion — 38,000 Notes payable, net of current portion 184,232 — Lease liabilities, net of current portion 723,497 — Total Liabilities 4,728,205 1,129,486 Commitments and Contingencies (Note 7) - - Stockholders' Deficit Common stock: $ 0.001 par value: 675,000,000 shares authorized: 277,945,910 and 277,112,660 issued and outstanding at December 31, 2023 and March 31, 2023, respectively 277,946 277,113 Additional paid-in capital 1,169,014 671,963 Accumulated deficit ( 5,323,023 ) ( 2,072,023 ) Total Stockholders' Deficit ( 3,876,063 ) ( 1,122,947 ) Total Liabilities and Stockholders' Deficit $ 852,142 6,539 The accompanying notes are an integral part of these unaudited financial statements. 1 REGENEREX PHARMA, INC. OP

NOTES TO FINANCIAL STATEMENTS

NOTES TO FINANCIAL STATEMENTS (UNAUDITED) NOTE 1 – NATURE OF OPERATIONS Regenerex Pharma, Inc., formerly Peptide Technologies, Inc. (the "Company" or "Regenerex"), was incorporated in the State of Nevada, United States of America, on November 18, 2005 . On November 15, 2021, the Company entered into an Asset Purchase Agreement in which the Company purchased certain intellectual property in exchange for 150,000,000 shares of the Company's common stock and up to $ 10,000,000 in contingent consideration to be paid at the rate of 15% of all gross revenues received from sales or investment money into the Company, payable on the 15 th of the following month, for a period of 60 months. The Company received all rights and title to proprietary wound healing technologies platforms and formulas involving the application of wound care protocols to treat all wounds, such as diabetic ulcers, pressure ulcers, burns and surgical wounds. These unique products strategically position the Company to enter the wound treatment market in the U.S. Risks and Uncertainties Our business and our forward-looking statements involve substantial known and unknown risks and uncertainties, including the risks and uncertainties inherent in our statements regarding the impacts of COVID-19, or other future pandemics on our business, results of operations, financial position, and cash flows. The Company has a lack of revenue history and has had a limited history of operations. No revenue has historically been derived from the assets purchased. Regenerex can give no assurance of success or profitability to the Company's investors. The wound care healing space is well suited for Home Care service providers that are funded by the US Government. Strategic planning and development will be performed internally by the Company. NOTE 2 – BASIS OF PRESENTATION OF INTERIM FINANCIAL STATEMENTS The Company prepares its financial statements in accordance with accounting principles generally accepted i

financial statements have been prepared in accordance with generally accepted

financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. In our opinion, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the nine months ended December 31, 2023, are not necessarily indicative of the results that may be expected for the year ending March 31, 2024. Notes to the unaudited interim financial statements that would substantially duplicate the disclosures contained in the audited financial should be read in conjunction with the audited financial statements and the footnotes thereto for the fiscal year ended March 31, 2023, included within the Company's Annual Report on Form 10-K as filed with the Securities and Exchange Commission. NOTE 3 – GOING CONCERN These financial accepted in the United States of America ("U.S. GAAP"), which contemplate the continuation of the Company as a going concern. The Company has incurred losses from operations, and as of December 31, 2023, it had excess liabilities over assets of $ 3,876,063 . These factors raise substantial doubt about the Company's ability to continue as a going concern. 5 The Company requires significant cash to launch its business and reduce its liabilities. Management's plans are to actively seek capital to enable the Company to add new products and/or services to ultimately achieve profitability. However, management cannot provide assurance that they can raise sufficient capital and whether the Company will ultimately achieve profitability, become cash flow positive, or raise additional debt and/or equity capital. If the Company is unable to raise additional capital in the near future or

View Full Filing

View this 10-Q filing on SEC EDGAR